Press Release

Evolve Biologics® Announces Appointment of New Chief Financial Officer 

September 6, 2022 Mississauga, ON, Canada – Evolve Biologics Inc. (“Evolve”), an innovative plasma-derived therapeutics company, is pleased to announce the appointment of Chris Carr as Chief Financial Officer. Chris will be responsible for all finance and accounting functions at Evolve and as a senior member of the executive team, Chris will be reporting to CEO Jim Caggiano.

Press Release

Evolve Biologics® Announces Site Selection, Land Purchase and Groundbreaking Ceremony for First Manufacturing Facility in Sachse, Texas

03 Dec, 2021 – Mississauga, ON, Canada (December 6, 2021) – Evolve Biologics Inc. (“Evolve”), an innovative plasma-derived therapeutics company, today announced the site selection, land purchase and groundbreaking ceremony for its first manufacturing facility in Sachse, Texas. This state-of-the-art facility will be the first to use Evolve’s innovative and proprietary technology, PlasmaCap EBA®, to commercially produce plasma-derived therapeutics, initially Intravenous Immunoglobulin (IVIG) and Human Serum Albumin (HSA).

Publication

Poster presented at the 10th Immunoglobulin National Society Conference (IgNS) 2021

Efficacy and Safety of PlasmaCap® IG (Immunoglobulin) Poster

22nd Oct 2021 – Las Vegas, NV (October 22nd, 2021) – Evolve presented updated results on behalf of Dr Richard Wasserman from the completed PlasmaCap IG Phase III Clinical Trial entitled “Efficacy and Safety of PlasmaCap IG, a New 10% Intravenous Immunoglobulin Manufactured Using an Innovative Chromatography Process, In Adults and Children with Primary Immunodeficiency Disorders”

Press Release

Evolve Biologics® Confirms Selection of DPR Construction as General Contractor for First Manufacturing Facility in Texas, Demonstrating Further Progress Toward Commercialization of its Innovative Plasmacap EBA® Technology

Evolve’s manufacturing facility to be located in Texas and first globally to use PlasmaCap EBA® technology in commercial-scale production of plasma-derived therapeutics  Innovative technology extracts plasma proteins more efficiently and at higher yields to improve the long-term reliable supply of critical plasma-derived therapeutics Mississauga, ON, Canada (May 17, 2021) – Evolve Biologics Inc. (“Evolve”), an innovative plasma-derived […]

Publication

Poster presented at Clinical Immunology Meeting (CIS) April 2021

Efficacy and Safety of PlasmaCap® IG poster

16 Apr, 2021 – Virtual Meeting (April 16, 2021) – Dr Richard Wasserman presented results from the completed PlasmaCap IG Phase III Clinical Trial entitled “Efficacy and Safety of PlasmaCap IG, a New 10% Intravenous Immunoglobulin Manufactured Using an Innovative Chromatography Process, In Adults and Children with Primary Immunodeficiency Disorders”. Abstracts available here

Press Release

Evolve Biologics Provides Business Update on Progress Toward Commercialization of Innovative Plasmacap EBA® Technology

10 Mar, 2021 – Mississauga, ON, Canada (March 10, 2021) – Evolve Biologics Inc. (“Evolve”), an innovative plasma-derived therapeutics company, today provided an update on its continued progress toward the development and commercialization of its PlasmaCap EBA technology and its strong position as an innovative developer and manufacturer of these critical products.

Press Release

Evolve Biologics® Completes Phase III Adult and Pediatric Trials for Plasmacap™ Ig (Intravenous Immunoglobulin)

09 Feb, 2021 – Mississauga, ON, Canada (February 9, 2021) – Evolve Biologics Inc. (“Evolve”), an innovative plasma-derived therapeutics company, today announced that it has successfully completed its adult and pediatric Phase III clinical trial of PlasmaCap IG (Intravenous Immunoglobulin or “IVIG”), conducted at 12 study centers across the U.S. and Canada. PlasmaCap IG is an investigational IVIG replacement therapy for adult and pediatric patients with primary immune deficiency disease (“PIDD”).

Press Release

Industry veteran Jim Caggiano appointed CEO of Evolve Biologics®, as company advances commercialization of innovative Plasmacap EBA® technology to disrupt $24 billion global plasma-derived therapeutics market

19 Jan, 2021 – Mississauga, ON, Canada (January 19, 2021) – Evolve Biologics Inc. (“Evolve”), an innovative plasma-derived therapeutics company, today announced the appointment of Jim Caggiano as CEO. Mr. Caggiano’s nearly 30 years of experience, bringing life-saving products to the market in the biotech, pharma and medical device industries, will help accelerate commercialization of the company’s PlasmaCap EBA technology, which stands to disrupt the global plasma-derived therapeutics market with its high-quality product yields at improved levels of efficiency and reliability compared to currently available technologies. Mr. Caggiano joins the company’s proven leadership team of David Holliday, Chief Commercial Officer, and Mark Krause, Head of Plasma Proteins.

Publication

Poster Presented at IgNS October 2019

PlasmaCap® IG (Immunoglobulin) Poster

25 Oct, 2019 – Las Vegas, NV (October 25, 2019) – Evolve presented “Interim results of a novel 10% liquid intravenous immune globulin (IVIG) product’s Phase III Prospective, Open-Label Multicenter Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics in Adults and Children with Primary Immunodeficiency Disease (PIDD)”. Abstracts available here.

Publication

Poster Presented at AAAAI February 2019

PlasmaCap™ IG (Immunoglobulin) Poster

24 Feb, 2019 – San Francisco, CA (February 24, 2019) – Dr Richard Wasserman presented “Interim Safety Data in a Prospective, Open-Label, Multi-Center Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of PlasmaCap IG in Patients with Primary Immunodeficiency Diseases (PIDDs)”. Abstract published in Journal of Allergy Clinical Immunology (JACI).